News

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

1 February 2024

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by EuroLand Corporate.

In a study entitled L’imagerie cellulaire à la loupe, EuroLand Corporate recommends Mauna Kea shares to Buy, with a target price of €0.71, representing an increase of +56% compared with the share’s closing price on January 31, 2024 (€0.456).

This new study adds to the consensus of financial analysts who already covers the stock alongside Portzamparc and Gilbert Dupont.

Latest News

Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround

Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround

Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

Mauna Kea Technologies Reports First Half 2025 Revenue 

Mauna Kea Technologies Reports First Half 2025 Revenue 

No results found.